Reimbursement, Procurement Models, and Cost-Effectiveness Considerations
Economic models matter in the Blood Screening Market. High-sensitivity molecular testing (NAT) and multiplex platforms improve safety but carry higher per-test costs. Payers, national health systems, and blood services must weigh upfront expenses against long-term savings from avoided infections, litigation, and repeat treatments. Outcome-focused procurement—evaluating cost per safe transfusion or cost per infection averted—helps justify investments in advanced screening. Leasing or reagent-rental models reduce capital barriers for smaller centers by shifting costs to operational budgets. Centralized national screening labs with satellite collection and POC prescreening are an increasingly adopted procurement strategy to balance quality and affordability. Vendor financing, public–private partnerships, and donor-supported programs can also accelerate adoption in lower-income regions. Clear evidence of cost-effectiveness, coupled with demonstrable reductions in transfusion risk, will remain essential for broad reimbursement and sustained market growth.
MRFR values: market was USD 2.70 billion (2023), USD 3.40 billion (2024); projected USD 5.60 billion by 2032 (CAGR 10.20%).